Sources:
Petrylak DP, Chi KN, Drakaki A, et al. RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. ESMO 2017 Congress, Abstract LBA4_PR.,Petrylak DP, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialThe Lancet. Published Online September, 12 2017. doi:10.1016/S0140-6736(17)32365-6.
Petrylak DP, Chi KN, Drakaki A, et al. RANGE: a randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma. ESMO 2017 Congress, Abstract LBA4_PR.,Petrylak DP, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialThe Lancet. Published Online September, 12 2017. doi:10.1016/S0140-6736(17)32365-6.